Dr Orod Osanlou
Clinical Reader in Medical Sciences (Pharmacology/Pharmacy)
Affiliations
Contact info
Dr Orod Osanlou is a Senior Clinical Lecturer in Pharmacology/Pharmacy at Bangor University. Amongst his university roles, he is the medical school Therapeutics Lead, and the Lead for the Prescribing Safety Assessment. As a Consultant in Clinical Pharmacology and Therapeutics, and General Internal Medicine, Dr Osanlou also works clinically at Betsi Calwaladr University Health Board. He is also the Director of the North Wales Clinical Research Facility, where there are opportunities for junior doctors and medical students to undertake placements and get invovled in research.
Contact Info
Dr Orod Osanlou is a Senior Clinical Lecturer in Pharmacology/Pharmacy at Bangor University. Amongst his university roles, he is the medical school Therapeutics Lead, and the Lead for the Prescribing Safety Assessment. As a Consultant in Clinical Pharmacology and Therapeutics, and General Internal Medicine, Dr Osanlou also works clinically at Betsi Calwaladr University Health Board. He is also the Director of the North Wales Clinical Research Facility, where there are opportunities for junior doctors and medical students to undertake placements and get invovled in research.
Research outputs (5)
- Published
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial
Research output: Contribution to journal › Article › peer-review
- Published
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial
Research output: Contribution to journal › Article › peer-review
- Published
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial
Research output: Contribution to journal › Article › peer-review